Bibliography
- Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511(7511):543-50
- Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014;25(3):282-303
- Stephen AG, Esposito D, Bagni RK, et al. Dragging ras back in the ring. Cancer Cell 2014;25(3):272-81
- Young A, McCormick F. Oncogenic and wild-type ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov 2013;3(1):112-23
- Ostrem JM, Peters U, Sos ML, et al. K-ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2014;503(7477):548-51
- Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2014;150(6):1107-20
- Zimmerman G, Papke B, Ismail S, et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signaling. Nature 2013;497(7451):638-42
- Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;454(7291):1067-70
- Yuan TL, Fellmann C, Lee CS, et al. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discovery 2014;4(10):1182-97
- Xue W, Dahlman JE, Tammela T, et al. Small RNA combination therapy for lung cancer. Proc Natl Acad Sci USA 2014;111(34):E3553-61
- Creelan BC. Update on immune checkpoint inhibitors in lung cancer. Cancer Contr 2014;21(1):80-9